GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amarin Corp PLC (NAS:AMRN) » Definitions » Beneish M-Score

Amarin (Amarin) Beneish M-Score : -2.80 (As of Apr. 29, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Amarin Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.8 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Amarin's Beneish M-Score or its related term are showing as below:

AMRN' s Beneish M-Score Range Over the Past 10 Years
Min: -2.91   Med: -2.5   Max: -0.36
Current: -2.8

During the past 13 years, the highest Beneish M-Score of Amarin was -0.36. The lowest was -2.91. And the median was -2.50.


Amarin Beneish M-Score Historical Data

The historical data trend for Amarin's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amarin Beneish M-Score Chart

Amarin Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.36 -0.94 -1.63 -1.87 -2.80

Amarin Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.87 -1.81 -2.63 -2.77 -2.80

Competitive Comparison of Amarin's Beneish M-Score

For the Drug Manufacturers - General subindustry, Amarin's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amarin's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amarin's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Amarin's Beneish M-Score falls into.



Amarin Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Amarin for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.2266+0.528 * 1.2177+0.404 * 0.5596+0.892 * 0.8313+0.115 * 0.9117
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.7901+4.679 * -0.068635-0.327 * 1.0597
=-2.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $133.6 Mil.
Revenue was 74.713 + 66.056 + 80.167 + 85.975 = $306.9 Mil.
Gross Profit was 45.124 + 29.822 + 42.668 + 47.927 = $165.5 Mil.
Total Current Assets was $725.0 Mil.
Total Assets was $831.7 Mil.
Property, Plant and Equipment(Net PPE) was $8.4 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.0 Mil.
Selling, General, & Admin. Expense(SGA) was $199.9 Mil.
Total Current Liabilities was $259.3 Mil.
Long-Term Debt & Capital Lease Obligation was $8.7 Mil.
Net Income was -5.781 + -19.311 + -17.56 + -16.46 = $-59.1 Mil.
Non Operating Income was -1.258 + -1.286 + -6.989 + 0.624 = $-8.9 Mil.
Cash Flow from Operations was -0.645 + 7.329 + 7.204 + -7.008 = $6.9 Mil.
Total Receivables was $131.0 Mil.
Revenue was 90.245 + 89.878 + 94.44 + 94.63 = $369.2 Mil.
Gross Profit was 63.604 + 62.859 + 43.63 + 72.391 = $242.5 Mil.
Total Current Assets was $689.1 Mil.
Total Assets was $886.2 Mil.
Property, Plant and Equipment(Net PPE) was $9.9 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.1 Mil.
Selling, General, & Admin. Expense(SGA) was $304.4 Mil.
Total Current Liabilities was $259.5 Mil.
Long-Term Debt & Capital Lease Obligation was $10.0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(133.563 / 306.911) / (130.99 / 369.193)
=0.435185 / 0.354801
=1.2266

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(242.484 / 369.193) / (165.541 / 306.911)
=0.656795 / 0.539378
=1.2177

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (724.981 + 8.424) / 831.684) / (1 - (689.098 + 9.948) / 886.179)
=0.118169 / 0.211168
=0.5596

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=306.911 / 369.193
=0.8313

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(3.096 / (3.096 + 9.948)) / (2.965 / (2.965 + 8.424))
=0.237351 / 0.260339
=0.9117

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(199.938 / 306.911) / (304.416 / 369.193)
=0.651453 / 0.824544
=0.7901

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((8.737 + 259.277) / 831.684) / ((10.015 + 259.479) / 886.179)
=0.322255 / 0.304108
=1.0597

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-59.112 - -8.909 - 6.88) / 831.684
=-0.068635

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Amarin has a M-score of -2.80 suggests that the company is unlikely to be a manipulator.


Amarin (Amarin) Business Description

Traded in Other Exchanges
Address
112-114 St Stephens Green, Iconic Offices, The Greenway, Block C Ardilaun Court, Dublin, IRL, D02 TD28
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its lead product includes Vascepa.
Executives
Steven B Ketchum officer: Chief Scientific Officer 2483 EAST BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
Patrick Holt director, officer: See Remarks C/O AMARIN CORPORATION, SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2 L2 D02 VK60
Oliver O'connor director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Paul Cohen director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Diane E. Sullivan director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Louis Iii Sterling director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Keith Horn director 204 STATE ROUTE 17B, P.O. BOX 5013, C/O MONTICELLO CASINO AND RACEWAY, MONTICELLO NY 12701
Patrice Eadon Bonfiglio director 488 HAVILAND ROAD, STAMFORD CT 06903
Mark Dipaolo director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Thomas Charles Reilly officer: SVP and CFO C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Aaron Berg officer: EVP, President US C/O AMARIN PHARMA, INC., 1430 ROUTE 206, BEDMINSTER NJ 07921
Karim Mikhail director, officer: President and CEO C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER NJ 08807
Olsen Per Wold director C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Murray Stewart director C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3